You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSpectinomycin
Accession NumberDB00919  (APRD01232)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Structure
Thumb
Synonyms
Actinospectacina
Espectinomicina
SCM
Spectinomicina
Spectinomycine
Spectinomycinum
External Identifiers
  • Antibiotic 2233wp
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trobicin Inj 400mg/mlPowder, for solution400 mgIntramuscularThe Upjohn Company Of Canada1972-12-311997-08-28Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ActinospectacinNot Available
SpectamNot Available
TogamycinNot Available
TrobicinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Spectinomycin dihydrochloride pentahydrate
ThumbNot applicableDBSALT001630
Spectinomycin hydrochloride
Thumb
  • InChI Key: BIPVCOUVVAMJMZ-MTTMTQIXSA-N
  • Monoisotopic Mass: 368.135028871
  • Average Mass: 368.811
DBSALT000380
Spectinomycin hydrochloride pentahydrate
ThumbNot applicableDBSALT001637
Spectinomycin sulfate tetrahydrate
ThumbNot applicableDBSALT001629
Categories
UNII93AKI1U6QF
CAS number1695-77-8
WeightAverage: 332.3496
Monoisotopic: 332.158351132
Chemical FormulaC14H24N2O7
InChI KeyUNFWWIHTNXNPBV-WXKVUWSESA-N
InChI
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
IUPAC Name
(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0³,⁸]tetradecan-7-one
SMILES
[H][C@@]12O[[email protected]](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[[email protected]](O)[C@@]1([H])O2
Pharmacology
IndicationFor use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae.
Structured Indications Not Available
PharmacodynamicsSpectinomycin is an aminocyclitol antibiotic produced by a species of soil microorganism designated as Streptomyces spectabilis. In vitro studies have shown spectinomycin to be active against most strains of Neisseria gonorrhoeae (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure.
Mechanism of actionSpectinomycin is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. It is bactericidal in its action.
TargetKindPharmacological actionActionsOrganismUniProt ID
30S ribosomal protein S12Proteinyes
inhibitor
Escherichia coli (strain K12)P0A7S3 details
Related Articles
AbsorptionRapidly and almost completely absorbed after intramuscular injection.
Volume of distributionNot Available
Protein bindingNot significant
MetabolismNot Available
Route of eliminationNot Available
Half life1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance < 20 mL per minute.
ClearanceNot Available
ToxicityAcute oral toxicity (LD50): >5000 mg/kg [Rat]. Information on overdosage in humans is not available.
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Spectinomycin Action PathwayDrug actionSMP00258
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Spectinomycin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Alendronic acidSpectinomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational
AmpicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Spectinomycin.Investigational
ApremilastApremilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Atracurium besylateSpectinomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Spectinomycin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
Botulinum Toxin Type ASpectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BSpectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Spectinomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Spectinomycin.Approved
CarbenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinSpectinomycin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateSpectinomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Spectinomycin.Approved
ClodronateSpectinomycin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateSpectinomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineSpectinomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
DecamethoniumSpectinomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Spectinomycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Spectinomycin.Approved
Domoic AcidSpectinomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideSpectinomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Spectinomycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Etidronic acidSpectinomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Spectinomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Spectinomycin.Approved, Vet Approved
Gallamine TriethiodideSpectinomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
IbandronateSpectinomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MecamylamineSpectinomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Spectinomycin can be decreased when it is combined with Meticillin.Approved
MetocurineSpectinomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideSpectinomycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumSpectinomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Spectinomycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
NeosaxitoxinSpectinomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Spectinomycin.Approved
OxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
PamidronateSpectinomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumSpectinomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spectinomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumSpectinomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Spectinomycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Spectinomycin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
PyrantelSpectinomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumSpectinomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental, Investigational
RisedronateSpectinomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumSpectinomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
SuccinylcholineSpectinomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Spectinomycin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Spectinomycin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateSpectinomycin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateSpectinomycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Spectinomycin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Spectinomycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateSpectinomycin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.Approved
TranilastTranilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TubocurarineSpectinomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Spectinomycin.Approved
VecuroniumSpectinomycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidSpectinomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

David R. White, “Intermediate compounds in the preparation of spectinomycin.” U.S. Patent US4344882, issued August, 1966.

US4344882
General ReferencesNot Available
External Links
ATC CodesJ01XX04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (24.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7118
Blood Brain Barrier-0.9892
Caco-2 permeable-0.6803
P-glycoprotein substrateNon-substrate0.526
P-glycoprotein inhibitor INon-inhibitor0.6468
P-glycoprotein inhibitor IINon-inhibitor0.9228
Renal organic cation transporterNon-inhibitor0.9646
CYP450 2C9 substrateNon-substrate0.7711
CYP450 2D6 substrateNon-substrate0.8496
CYP450 3A4 substrateNon-substrate0.5056
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9182
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9254
Ames testNon AMES toxic0.7167
CarcinogenicityNon-carcinogens0.9602
BiodegradationNot ready biodegradable0.983
Rat acute toxicity1.8538 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Non-inhibitor0.9493
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntramuscular400 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityEasily soluble in cold waterNot Available
logP-2.3Not Available
pKa6.95MERCK INDEX (1996); pKa1
Predicted Properties
PropertyValueSource
Water Solubility150.0 mg/mLALOGPS
logP-1.4ALOGPS
logP-2.4ChemAxon
logS-0.35ALOGPS
pKa (Strongest Acidic)8.58ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area129.51 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity75.44 m3·mol-1ChemAxon
Polarizability33.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassCyclohexylamines
Sub ClassNot Available
Direct ParentCyclohexylamines
Alternative Parents
Substituents
  • Cyclohexylamine
  • Oxane
  • Para-dioxane
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Ketone
  • Hemiacetal
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yamagata H, Dombou M, Sato T, Mizushima S, Uchida H: Deletion mapping and heterogenote analysis of a mutation responsible for osmosis-sensitive growth, spectinomycin resistance, and alteration of cytoplasmic membrane in Escherichia coli. J Bacteriol. 1980 Aug;143(2):661-7. [PubMed:6451613 ]
  4. Gordeev VK, Turkov MI: [Functioning of amino acid operons in Escherichia coli strains with an altered transcription and translation apparatus. II. The effect of mutations in genes coding ribosomal protein S5 and translation elongation factor G on the functioning of the ilv operon]. Genetika. 1983;19(2):217-20. [PubMed:6339322 ]
  5. Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [PubMed:6103875 ]
  6. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. [PubMed:11014183 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23